Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 3/20 | 0.52 |
| ▸ | GABRD | O14764 | 3/20 | 0.52 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.52 |
| ▸ | GABRB1 | P18505 | 3/20 | 0.52 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.52 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.52 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.52 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.52 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.52 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.52 |
| ▸ | GABRA4 | P48169 | 3/20 | 0.52 |
| ▸ | GABRE | P78334 | 3/20 | 0.52 |
| ▸ | GABRA6 | Q16445 | 3/20 | 0.52 |
| ▸ | GABRG1 | Q8N1C3 | 3/20 | 0.52 |
| ▸ | GABRG3 | Q99928 | 3/20 | 0.52 |
| ▸ | GABRQ | Q9UN88 | 3/20 | 0.52 |
| ▸ | GABRR1 | P24046 | 4/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.46 |
| ▸ | GSR | P00390 | 2/20 | 0.46 |
| ▸ | GRM8 | O00222 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| D-Alanine SCHEMBL1512857 | 1.00 | GABRP (0.52) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| Alanine SCHEMBL6754143 | 1.00 | GABRP (0.52) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| Alanine SCHEMBL9957817 | 1.00 | GABRP (0.52) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| Alanine SCHEMBL7547184 | 0.95 | GABRP (0.48) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| Alanine SCHEMBL7547179 | 0.95 | GABRP (0.48) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| Beta-Alanine SCHEMBL27717619 | 0.90 | GABRP (0.56) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| Valine SCHEMBL20212334 | 0.89 | SLC7A5 (0.60) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| Succinic Acid SCHEMBL542249 | 0.87 | GABRP (0.59) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| Succinic Acid SCHEMBL542280 | 0.87 | GABRP (0.59) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| Succinic Acid SCHEMBL542250 | 0.87 | GABRP (0.59) | GABRPGABRDGABRA1GABRB1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3736275-B1 | OXABICYCLOHEPTANE PRODRUGS FOR USE IN TREATING CANCER | LIXTE BIOTECHNOLOGY INC (US) | 2024-07-03 | — | — | EP | disclosed |
| US-11866444-B2 | Oxabicycloheptane prodrugs | LIXTE BIOTECHNOLOGY, INC. (US) | 2024-01-09 | — | — | US | disclosed |
| WO-2023178313-A2 | RADIOPHARMACEUTICAL COMPOSITIONS, SYNTHETIC METHODS, AND METHODS OF TREATMENT | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2023-09-21 | — | — | WO | disclosed |
| WO-2023070004-A1 | TARGETED RADIOTHERANOSTICS BASED ON POLYAZAMACROCYCLIC, MIXED-DONOR SCAFFOLDS LINKED TO A TARGETING VECTOR | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2023-04-27 | — | — | WO | disclosed |
| WO-2022186652-A1 | METHOD AND KIT FOR DIAGNOSING DIABETES BY USING TEARS | 경희대학교 산학협력단 | 2022-09-09 | — | — | WO | disclosed |
| US-20220218661-A1 | COMPOSITIONS AND METHODS FOR MODULAR CONTROL OF BIOORTHOGONAL LIGATION | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2022-07-14 | — | — | US | disclosed |
| US-11236102-B2 | Oxabicycloheptane prodrugs | LIXTE BIOTECHNOLOGY, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-20210276971-A1 | TRIAZAMACROCYCLE-DERIVED CHELATOR COMPOSITIONS FOR COORDINATION OF IMAGING AND THERAPY METAL IONS AND METHODS OF USING SAME | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2021-09-09 | — | — | US | disclosed |
| CN-113150030-A | Oxabicycloheptane prodrugs | 莱克斯特生物技术公司 | 2021-07-23 | — | — | CN | disclosed |
| US-10954273-B2 | Hybrid cyclic libraries and screens thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-03-23 | — | — | US | disclosed |
| US-20140154693-A1 | REAGENT USABLE FOR THE ISOLATION AND/OR PURIFICATION OF NUCLEIC ACIDS | QIAGEN GMBH (DE) | 2014-06-05 | — | — | US | disclosed |
| EP-2729570-A2 | REAGENT USABLE FOR THE ISOLATION AND/OR PURIFICATION OF NUCLEIC ACIDS | Qiagen GmbH (DE) | 2014-05-14 | — | — | EP | disclosed |
| WO-2014047199-A1 | NOVEL PRODRUGS FOR SELECTIVE ANTICANCER THERAPY | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2014-03-27 | — | — | WO | disclosed |
| WO-2014027012-A1 | METHOD FOR PRODUCING A COMPOSITION FOR TREATING A TOOTH LESION | CREDENTIS AG (CH) | 2014-02-20 | — | — | WO | disclosed |
| US-20130309732-A1 | BIOSYNTHESIS METHODS OF NOREPHEDRINE WITH SPECIFIC OPTICAL ACTIVITIES | HUNGKUANG UNIVERSITY (TW) | 2013-11-21 | — | — | US | disclosed |
| EP-2647713-A1 | MODIFIED SINGLE-STRAND POLYNUCLEOTIDE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-10-09 | — | — | EP | disclosed |
| US-20130253038-A1 | Modified Single-Stranded Polynucleotide | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-09-26 | — | — | US | disclosed |
| WO-2013004710-A2 | REAGENT USABLE FOR THE ISOLATION AND/OR PURIFICATION OF NUCLEIC ACIDS | QIAGEN GMBH (DE) | 2013-01-10 | — | — | WO | disclosed |
| EP-2348080-A1 | Polishing composition and polishing method using the same | FUJIMI INCORPORATED (JP) | 2011-07-27 | — | — | EP | disclosed |
| WO-2009145839-A1 | POLYAMINE COMPOUNDS THAT BIND TAR RNA OF HIV AND METHODS OF TREATING VIRAL DISORDERS | GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2009-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220218661-A1 | COMPOSITIONS AND METHODS FOR MODULAR CONTROL OF BIOORTHOGONAL LIGATION | CBR3, C1R, CBR1 | GABRP 3263/4885GABRD 1964/4885GABRA1 958/4885 |
| US-10954273-B2 | Hybrid cyclic libraries and screens thereof | CACYBP, HSPBP1, PEBP1 | GABRP 2059/4885GABRD 2797/4885GABRA1 4228/4885 |
| US-11866444-B2 | Oxabicycloheptane prodrugs | UGT2B7, UGT1A6, UGT1A1 | GABRP 1145/4885GABRD 2500/4885GABRA1 2611/4885 |
| US-20210276971-A1 | TRIAZAMACROCYCLE-DERIVED CHELATOR COMPOSITIONS FOR COORDINATION OF IMAGING AND THERAPY METAL IONS AND METHODS OF USING SAME | PAICS, SLC39A14, SLC39A7 | GABRP 2019/4885GABRD 2790/4885GABRA1 2015/4885 |
| US-11236102-B2 | Oxabicycloheptane prodrugs | UGT2B7, UGT1A6, UGT1A1 | GABRP 1145/4885GABRD 2500/4885GABRA1 2611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.